Cargando…
Ertapenem non-susceptibility and independent predictors of the carbapenemase production among the Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)
OBJECTIVES: This study investigated the prevalence rates of carbapenemase positivity, antibiotic susceptibility, and independent predictors of carbapenemase producers among the Enterobacteriaceae isolates recovered from patients with intra-abdominal infections (IAI) in the Asia-Pacific region betwee...
Autores principales: | Jean, Shio-Shin, Lee, Wen-Sen, Hsueh, Po-Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203167/ https://www.ncbi.nlm.nih.gov/pubmed/30425537 http://dx.doi.org/10.2147/IDR.S181085 |
Ejemplares similares
-
2266. Management of Ertapenem-Resistant, Meropenem-Susceptible Enterobacteriaceae
por: Srinivas, Pavithra, et al.
Publicado: (2019) -
Screening for Carbapenemases in Ertapenem-Resistant Enterobacteriaceae Collected at a Tunisian Hospital Between 2014 and 2018
por: Kollenda, Hans, et al.
Publicado: (2019) -
Antimicrobial Susceptibility of E. coli Isolates from Intra-Abdominal Infections in the Asia-Pacific Region: Trends in Ciprofloxacin, Ceftriaxone, Cefepime, and Piperacillin/Tazobactam Susceptibility
por: Tsai, Chia-Hung, et al.
Publicado: (2023) -
Difference in Susceptibility Between Carbapenemase- and Non–Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
por: Clark, Justin, et al.
Publicado: (2021) -
Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)